Title: Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus: a Cohort Study

Authors:
[1,4]Marcus N. Callister M.D.
[2]Molly C. Klanderman Ph.D., M.S.
[3]Alyssa Stockard, B.S.
[2]Charles Van Der Walt, B.S.
[1,5]Ashley B. Pena M.D.
[1]John N. Caviness M.D.

Affiliations:
[1]Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
[2]Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA
[3]Alix School of Medicine, Mayo Clinic, Scottsdale, Arizona, USA
[4]Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
[5]Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA

Corresponding author:
Marcus N. Callister, M.D.
Chen Lab, 12 MC 421, Toronto Western Hospital, University of Toronto
399 Bathurst St, Toronto, ON M5T 2S8, Canada
Email: marcus.callister@uhn.ca
Phone: 801-543-9025
Fax: 445-999-5650

Abstract

Objective

Careful examination is not always able to distinguish myoclonus, tremor, and other jerky movements. Movement neurophysiology studies utilizing surface electromyography and electroencephalography can clarify movement classification, however there has been limited demonstration of their real-world impact on diagnosis and treatment. We investigated their clinical utility in changing jerky movement classification and influencing patient management.

Methods

Retrospective single-center study of all myoclonus-related movement studies from 2007-2021, with extraction from reports and clinical documentation.

Results

Of 262 patients referred for movement studies for consideration of myoclonus, 105 (40%) had myoclonus, 156 (59%) had no myoclonus (the commonest alternative classifications were functional jerks and tremors), and 1 was uncertain. An additional 29 cases found myoclonus without prior clinical suspicion; this was significantly more common among referrals from non-movement specialty neurologists (15/64, 23%), but also occurred in movement specialist referrals (14/227, 6%, $p < 0.001$). 119/134 (89%) myoclonus cases had a specific physiologic subtype identified, the commonest were cortical (64, 54%) confirmed by cortical transient in 98%, subcortical/non-segmental (22, 18%), and segmental (15, 13%). Diagnostic differential narrowed in 60% of cases, and a new diagnosis (not suspected prior to the movement study) was made in 42 (14%) patients. Medication changes (most commonly guided by myoclonus physiologic subtype) were made in 151 patients (52%), with improvement in 35/51 (67%) with follow-up.

Interpretation

Movement studies effectively clarified movement classification and identified unsuspected myoclonus, leading to changes in diagnosis and management. Myoclonus physiologic subtypes led to targeted medication selection and successful treatment in many cases.

Introduction

Myoclonus is a hyperkinetic abnormal movement characterized by brief, involuntary, jerk-like movement of one or more body parts.[1] Etiologic categories of myoclonus include physiologic, hereditary, epileptic, and symptomatic, the latter spanning an extraordinarily broad range of causes including degenerative, inflammatory, metabolic, toxic, drug-induced, focal neurologic damage, and more.[2] Identification and treatment of myoclonus can present challenges to clinicians. Thorough history and physical examination cannot always distinguish myoclonus from other hyperkinetic movement classifications such as tremor, dystonia, fasciculations, functional neurologic disorder (FND), and sudden spasms.[3] Once myoclonus is identified, the breadth of conditions where myoclonus can manifest provokes a diagnostic odyssey which may conclude with "idiopathic", leaving uncertainty regarding the optimal treatment strategy.

Movement neurophysiology studies (MNS) have been essential in research investigation of myoclonus physiology,[4–6] and in some tertiary centers clinical MNS are available to aid in the evaluation of patients with suspected myoclonus and other abnormal movements. MNS utilize surface electromyography (EMG), accelerometry, electroencephalography (EEG), and other tools to measure movement characteristics and corresponding muscle and brain activity.[7] MNS can definitively identify myoclonus and differentiate its physiological classification and origin, including cortical, cortical-subcortical, subcortical/non-segmental, segmental, and peripheral (Table 1).[1] Myoclonus physiologic subtyping based on specific MNS findings has been validated against expert clinician diagnosis,[8] and myoclonus specialized tests such as EMG-EEG back-averaging have high specificity.[9] Physiologic subtyping can narrow the diagnostic search to etiologies associated with that myoclonus subtype.[2] Subtyping can also guide treatment choices, as certain medications have shown efficacy for specific physiologic subtypes of myoclonus regardless of etiology.[10]

Despite providing these clinically relevant insights, clinical MNS for myoclonus identification and subtyping has seen limited uptake and availability is limited. Reasons include lack of specialized training and equipment required to perform and interpret these studies, as well as lack of reimbursement schemes.[11,12] A majority of movement specialists perceive movement neurophysiology as clinically valuable and cost-beneficial,[12] and prior research has confirmed that MNS frequently result in changes in hyperkinetic movement classification,[13–15] but there has been limited demonstration of how this impacts real-world clinical management, particularly for myoclonus physiologic subtyping. MNS have been available at the Mayo Clinic in Arizona for clinical evaluation of patients with suspected myoclonus and other abnormal movements in the outpatient and inpatient settings since 1992. This study aimed to investigate the impact of MNS on clinical practice including diagnosis and treatment decisions in a novel way by examining retrospective data from patients referred for MNS at our center from 2007-2021.

Methods

Our standard clinical MNS set-up includes an EEG cap with expanded motor cortex leads and bipolar surface EMG leads with standardized placement on 8 muscles in each upper limb and 4 muscles on each lower limb. Additional EMG leads can be placed on the face, neck, and/or trunk as needed, and a single uniaxial accelerometer can be added. For each study, cap and lead placement is performed by 1-2 clinical neurophysiology technicians with training in movement neurophysiology studies and ongoing experience in EEG and nerve conduction studies, and a standardized protocol recording the patient at rest and during specific movements is conducted by a clinical neurophysiology technician with live in-person supervision and MNS data review by the movement neurophysiology neurologist (author JNC) (detailed set-up and protocol information can be found in Supplement 1).

A cohort of subjects including all patients evaluated in the MNS lab at Mayo Clinic in Arizona from 01 January 2007 through 15 September 2021 was identified using practice billing records. Patients with billing codes indicating that myoclonus was identified on MNS were extracted for chart review. To find patients who were referred for MNS for suspected myoclonus, but myoclonus was not found, we used a specialized electronic health record (EHR) analytic tool (Advanced Text Explorer, Mayo Clinic) to search the remaining MNS patient charts for mentions of the term "myoclonus." We reviewed each mention to evaluate whether myoclonus was part of the MNS referral question, or if the mention was irrelevant (e.g. "There was no myoclonus on exam"). If the mention appeared to be relevant, the chart was reviewed in further detail to confirm that MNS was ordered for suspected myoclonus. For both myoclonus and non-myoclonus patients, exclusion criteria included repeat studies for patients who had previous MNS (as the focus of our investigation was on the utility of a single first-time MNS), patients where the target movement was not captured on MNS (most often because movements resolved prior to MNS), and patients without a pre-MNS consult or post-MNS follow-up note (Fig 1). Studies in which there was no suspicion for myoclonus pre-MNS and no myoclonus found on MNS were not included in this investigation.

Retrospective data collection from EHR clinical notes and MNS reports was performed by 2 study authors (MNC and AS) using a customized Research Electronic Data Capture (REDCap) instrument, the full instrument is included in Supplement 2. Authors reviewed pre-MNS records (mainly consultation notes) for demographics, date of movement onset, MNS-referring clinician type (movement specialty neurologist, non-movement neurologist, or non-neurologist), and clinical exam findings; reviewed MNS reports for study set-up, use of myoclonus-specific tests, and neurophysiologic data results; reviewed post-MNS records (mainly follow-up notes) for clinician type, agreement/disagreement with MNS finding and discussion of their clinical significance and impact on diagnosis and treatment decision making, recommended additional diagnostic tests, referrals, and medication changes; and reviewed all records for visit setting (in-person or telemedicine), movement classification(s), and clinical diagnostic differential. If a medication change was made post-MNS, the subsequent follow-up note (if available) was reviewed for response to medication change (very much improved, somewhat improved, no change, somewhat worse, or very much worse) and adverse effects (no adverse effects, mild adverse effects not requiring adjustment of the treatment plan, moderate adverse effects prompting adjustment of the treatment plan, or severe adverse effects requiring medical intervention). Myoclonus subtypes and other movement classifications were collected as stated in MNS reports and clinician notes, and were not retrospectively re-classified by study authors: MNS features used in movement classification have been consistent at our center over the study time period (Table 1) and are in alignment with current published recommendations.[1] Certainty regarding the presence of myoclonus pre-MNS, MNS, and post-MNS was categorized as: a) specific myoclonus neurophysiologic subtype identified, b) myoclonus (subtype indeterminate) identified/strongly suspected, c) possible/uncertain/rule-out myoclonus, or d) no suspicion of myoclonus. Diagnostic differential was categorized as a) single specific diagnosis, b) narrow differential (<=3 possible diagnoses), c) broad differential (>3 possible diagnoses), or d) uncertain or unspecified. Clinician response to MNS findings at post-MNS follow-up was categorized as: a) specifically discussed the clinical significance and implications of the MNS findings in their diagnostic reasoning and treatment decision making, b) mentioned the MNS results but did not comment on their clinical significance, c) mentioned that the MNS was done without any description of the MNS results, d) no mention of the MNS at all in the follow-up note, or e) disagreed with the MNS findings and/or interpretation. Medical, surgical, and family history data were extracted for all patents with post-MNS classification of myoclonus.

Categorical variables were summarized with frequency count and percentage. Continuous variables were summarized using mean with standard deviation for normally distributed data, or median with interquartile range (IQR) for non-normally distributed data. Alluvial plots were constructed to illustrate shift in myoclonus certainty and diagnostic differential from pre-MNS to post-MNS. For each myoclonus subtype, we identified the most common medications prescribed/increased and discontinued/decreased. Univariate tests were conducted using linear model analysis of variance (ANOVA) for continuous variables and Fisher's exact test for categorical variables. A p-value of <0.05 was considered to be significant. R Statistical Software version 4.2.2 was used for analysis.

STROBE cohort reporting guidelines were used for research and manuscript preparation.[16]

The Mayo Clinic Institutional Review Board approved this study (IRB 18-002646), requirement for consent was waived due to retrospective data collection design.

Results

Practice billing records showed that there were 1,294 MNS in total performed from 2007-2021. After exclusions and screening for presence of myoclonus in the MNS referral and/or MNS results (Fig 1), 291 patients were included in the study. Demographics and summary clinical data are presented in Table 2. Patients whose final post-MNS classification was myoclonus were significantly older than those with a non-myoclonus classification (median age 58 vs 53, p = 0.021), other demographic differences were not statistically significant. Detailed chart review of the 135 patients with post-MNS classification of myoclonus (including 1 with uncertain myoclonus post-MNS) revealed:

- Median duration of abnormal movements was 12 months (IQR 5-42 months)
- 34% had documented neurologic comorbidities: the most common were migraine in 10%, seizures 8%, dementia 7%, and neuropathic pain 6%
- 17% had psychiatric comorbidities: the most common was depression/anxiety in 14%
- 36% had medical comorbidities: the most common were elements of metabolic syndrome (hypertension, dyslipidemia, and/or obesity) in 16%, cardiac disease 15%, thyroid disorders 12%, and sleep disorder 11%
- 7% had neurological surgery history: the most common was spine surgery in 4%
- 16% had family history of neurological disease, including 7% with family history of a movement disorder, and none had documented family history of myoclonus
- 56% of post-MNS myoclonus patients had other abnormalities on pre-MNS neurologic exam besides the hyperkinetic movement(s), including gait/balance impairment, bradykinesia, sensory loss, and increased tone, compared to 4% of the post-MNS non-myoclonus patients

MNS referrals were all internal, most commonly from movement specialty neurologists (227, 78%) including 102 (35%) from the movement neurophysiology neurologist (study author JNC), with the remainder from other neurologists (64, 22%) and no direct referrals from non-neurologists. Pre-MNS consultation was documented as in-person in 98% of cases and telemedicine in 2%. Of the 262 patients referred for MNS for consideration of myoclonus, the largest portion were referred for possible/uncertain/rule-out myoclonus (187/262, 71%), 67 (26%) for clinical identified/strongly suspected myoclonus (subtype indeterminate), and a small minority (8, 3%) were referred for a specified clinically identified physiologic subtype of myoclonus (Fig 2). Among these 262 MNS referrals for consideration of myoclonus, 146 (56%) had alternative movement classifications in the pre-MNS movement classification differential, and 60 (23%) were suspected to have multiple coexisting movement classifications (e.g.

myoclonus and tremor). The most common pre-MNS differential/coexisting movements were muscle activation tremor (93, 35%), FND (46, 18%), and dystonia (25, 10%). An additional 29 patients had myoclonus identified on MNS without any pre-MNS suspicion for myoclonus. For these patients, the most common referral reasons were muscle activation tremor (13, 45%), rest tremor (5, 17%), and enhanced physiologic tremor (4, 14%).

Among all 291 patients in the study, pre-MNS clinical diagnostic differential was a single specific diagnosis in 28 (10%), narrow differential (<=3 possible diagnoses) in 64 (22%), broad differential (>3 possible diagnoses) in 117 (40%), and uncertain/unspecified in 82 (28%).

MNS set-up included EEG with expanded motor cortex leads in all patients, and bipolar surface EMG leads on 8 muscles in each upper limb and 4 muscles on each lower limb in all patients (except 3 patients with more limited limb EMG leads). Additional EMG leads were placed on the face, neck, and/or trunk in 89 (30%) patients, and accelerometry was used in 55 (19%) patients (detailed set-up information can be found in Supplement 1). Needle EMG was not utilized in any MNS in this study. The vast majority of MNS (277, 95%) were performed by the movement neurophysiology neurologist (study author JNC) with or without a clinical fellow assisting, and the remaining 14 (5%) were performed by another movement neurophysiology neurologist.

MNS reported findings included myoclonus in 133 cases (with a subtype specified in 120), uncertain myoclonus in 1 case (fragmentary myoclonus vs fasciculations, coexisting with definite orthostatic tremor), and no myoclonus in 157 cases. In post-MNS follow-up, clinicians' movement classification agreed with the MNS report classification and myoclonus subtype in 289 (99%) cases, and disagreed in 2 cases. In 1 of these cases with disagreement, MNS reported no myoclonus, but the clinician (a neuromuscular specialist) disagreed with the MNS interpretation and maintained suspicion for myoclonus (subtype indeterminate); and in 1 case MNS reported subcortical/non-segmental myoclonus, but the clinician left the classification as myoclonus subtype indeterminate without specifically discussing their reasoning. As a result, the final post-MNS conclusion was 134 cases myoclonus (119 subtype specified), 1 case uncertain myoclonus, and 156 cases no myoclonus.

MNS neurophysiologic data for the 134 post-MNS myoclonus cases are presented in Table 3. All cases of cortical myoclonus with documentation of EMG burst duration included discharges <100 msec, 5 (8%) cases also had some bursts >100 msec. Burst duration was most commonly >100 msec for subcortical/non-segmental myoclonus and segmental myoclonus, but there were 6 (27%) cases of subcortical/non-segmental myoclonus and 2 (13%) cases of segmental myoclonus where all bursts were <100 msec duration. Myoclonus location was most commonly multiple limbs across all subtypes, except for segmental myoclonus which most commonly involved the trunk. The 22 cases of subcortical non-segmental myoclonus included 5 cases of propriospinal myoclonus, 2 cases of hypnic jerks, and 15 other cases. Cortical-subcortical myoclonus was seen in only 1 patient: MNS showed generalized jerks with EMG burst duration >100 msec correlated with generalized spike and wave discharges on raw EEG, , with coexisting separate cortical myoclonus jerks with EMG burst duration 50-75 msec correlated with back-averaged cortical transient, in the setting of epilepsy. No cases of peripheral myoclonus were identified, as hemifacial spasm and related conditions are referred to a separate clinical neurophysiology lab at our center. 17 patients were classified as fragmentary myoclonus: the electrophysiological origin of this movement has not been settled, and so it was categorized separately. 1 case of orthostatic myoclonus was seen, which demonstrated burst duration <50 msec and a cortical transient on back-averaging, and so was classified as cortical myoclonus. In 15 patients, the myoclonus subtype was unable to be determined due to overlapping features of different subtypes, including short duration with no cortical transient on technically adequate EMG-EEG back-averaging (7 cases), infrequent jerks limiting back-averaging (7

cases), or inability to distinguish infrequent myoclonus from irregular tremor beats preventing reliable back-averaging (1 case). Coexisting muscle activation tremor and other coexisting non-myoclonus abnormal movements were common (57/134, 43%), especially in myoclonus subtype-indeterminate cases (10/15, 66%), where the non-myoclonus movements were often dominant.

Results of myoclonus-specific neurophysiologic tests are also presented in Table 3. A cortical transient associated with myoclonus EMG discharges was present on raw EEG (without EMG-EEG back-averaging) in 1 case, confirming cortical myoclonus. EMG-EEG back-averaging was attempted in 111 patients and demonstrated a cortical transient confirming cortical myoclonus in 62 (56%) cases, including 14 patients where myoclonus had not been suspected pre-MNS. In 1 additional case with infrequent myoclonus discharges intermixed with tremor, back-averaging was suggestive of a cortical transient but not definitive; the case was classified as cortical myoclonus given this suggestive EEG finding as well as burst duration <50 msec and multifocal distribution. Therefore, in total 63/64 (98%) cases of cortical myoclonus were confirmed by a definitive cortical transient on EEG (raw or back-averaged). Back-averaging in 31 (28%) technically adequate studies showed no cortical transient, ruling out cortical myoclonus. Back-averaging was limited due to infrequent jerks in 12 (8%) cases or by other technical factors in 5 (4%) cases: several of these were classified as fragmentary myoclonus (n=4), segmental myoclonus (n=1), or subcortical/non-segmental myoclonus (n=1) based on other MNS features, the remainder were classified as myoclonus subtype unspecified (n=8) or no myoclonus (n=3). Somatosensory evoked potential (SSEP) was attempted in 23 patients and was enlarged in 6 patients, all of whom also had a cortical transient on back-averaging, and SSEP was normal in 17 cases, including 14 cases where a cortical transient was present. Long latency reflex (LLR) was evaluated in 20 patients and was enhanced in 8 patients, all of whom also had a cortical transient on back-averaging, and LLR was normal in 12 cases, all of which had a cortical transient present. SSEP and LLR were never pursued in the absence of EMG-EEG back-averaging. There were no cases where a cortical transient was absent and SSEP or LLR were abnormal. Corticomuscular coherence analysis was attempted in only 3 cases, and was absent in all (1 classified as subcortical/non-segmental myoclonus, 2 as non-myoclonus). Epileptiform discharges were incidentally noted on EEG in 5 (2%) cases, 3 of these already had known seizure disorders.

For the 156 cases referred for myoclonus who had no myoclonus post-MNS, a variety of movement classifications were identified (Table 4), the most common were functional jerks or other FND (54, 35%), tremor in activation (45, 29%), and tremor in rest (20, 13%). 35 (22%) cases had multiple co-existing abnormal movement classifications, and in 10 (3%) cases the MNS and post-MNS follow-up were unable to determine the abnormal movement classification beyond a differential. EMG-EEG back-averaging for a Bereitschaftspotential was attempted in 10 cases of FND and was present in 8 cases.

Post-MNS follow-up was done by the same neurologist as pre-MNS consultation and MNS referral in 277 (95%) cases, and by a different neurologist in 14 (5%) cases, most commonly via referral from a non-movement specialist to a movement specialist. Follow-up was documented as in-person in 91% of cases and telemedicine in 7%. Clinician myoclonus classification shift from pre-MNS to post-MNS is illustrated in Figure 2 for patients referred by movement and non-movement neurology. Of the 29 patients found to have myoclonus on MNS without any pre-MNS suspicion for myoclonus, a significantly larger portion were among the referrals from non-movement specialty neurologists (15/64 non-movement MNS referrals, 23%) than from movement neurologists (14/227, 6%, p <0.001). 23/29 had a specific myoclonus subtype identified, and 18/29 had other coexisting movement classifications. Conversely, of the 156 patients with no myoclonus post-MNS, 24 (15%) had been referred for MNS with myoclonus as the only movement classification under consideration (clinically identified/strongly suspected in 9 [38%],

possible/uncertain in 15 [63%]), without any other abnormal movement classifications specified as a differential.

In 248 (85%) of cases, the neurologist specifically discussed the clinical significance and implications of the MNS findings in their diagnostic reasoning and treatment decision making. For the remainder, in 30 (10%) the neurologist mentioned the MNS results but did not comment on their clinical significance, in 4 (1%) cases there was only a mention that the MNS was done without any description of the MNS results, in 8 (3%) cases there was no mention of the MNS at all, and in only 1 case the neurologist (a neuromuscular specialist) specifically described how they disagreed with the MNS interpretation.

Shift in diagnostic differential is illustrated in Figure 3 for patients referred by movement and non-movement neurology. 28 (10%) patients had a single specific diagnosis pre-MNS, while post-MNS 163 (56%) patients had a single specific diagnosis, of these 42 (14%) had a new single diagnosis which had not been suspected in the differential pre-MNS. This was significantly more common among non-movement referrals (15/64, 23%) than movement referrals (27/227, 12%, p=0.027). An additional 29 (10%) patients had a new diagnosis added to the clinical differential (narrow or broad) post-MNS which had not been suspected pre-MNS, for a total of 71 (24%) cases with new diagnostic considerations post-MNS. Differential narrowing (e.g. broad to narrow, narrow to single) from pre-MNS to post-MNS was seen in 174 (60%) patients, compared to broadening (e.g. narrow to broad, broad to unknown) in 31 (11%) patients, while differential breadth remained the same in 86 (29%). Diagnostic differential for each myoclonus subtype is summarized in Table 5.

Among all subjects, 39 (13%) patients had additional diagnostic testing ordered post-MNS, including spinal MRI (12, 4%), lumbar puncture (11, 4%), genetic testing (5, 2%), brain MRI (5, 2%), and other imaging (6, 2%). 56 (19%) patients had referrals ordered post-MNS, most commonly to psychiatry (31, 11%) or physical/occupational therapy (16, 5%). 151 (52%) patients had medication changes made post-MNS, including 125 (43%) patients where a new medication was started or an existing medication increased, and 46 (16%) patients where an existing medication was discontinued or decreased, with some overlap. The most common medication changes for each myoclonus subtype are given in Table 5. Cortical myoclonus was more likely to be prescribed levetiracetam than any other medication (18/39 [46%] medication start/increase changes), and correspondingly levetiracetam was prescribed more commonly for cortical myoclonus than for any other myoclonus type (18/26 [69%] levetiracetam start/increase changes). Patients with segmental myoclonus or subcortical/non-segmental myoclonus were more likely to be prescribed benzodiazepines than any other medication (6/11 [55%] and 4/12 [33%] medication start/increase changes respectively). Individual medication-subtype associations were not common enough to compare and test for statistical significance.

Of the 151 patients with post-MNS medication changes, 51 (34%) had follow-up documenting clinical response. 25 (49%) were very much improved, 10 (20%) were somewhat improved, and 16 (31%) were unchanged, no patients were documented to be worse after medication changes. 42 (14%) patients had documented evaluation for adverse effects at follow-up, 21 (50%) had no adverse effects, 11 (26%) had mild adverse effects, 24% had moderate adverse effects prompting adjustment of the treatment plan, and no patients were documented as having severe adverse effects. Medication responses for each myoclonus subtype are summarized in Table 5.

Discussion

To our knowledge, this investigation represents the largest collection of myoclonus cases with movement neurophysiology characterization, and is the first to comprehensively demonstrate the clinical utility of MNS findings in the real-world setting.

The primary reason for MNS referral was uncertainty regarding movement classification, and MNS effectively clarified this: prior to MNS 187 cases were possible/uncertain myoclonus and 146 cases had a differential of multiple movement classifications, while post-MNS only 1 cases was possible/uncertain myoclonus (Fig 2) and 10 cases had a differential of multiple movement classifications (all non-myoclonus). *In 29 cases myoclonus was identified on MNS where there had been no suspicion of myoclonus pre-MNS, this was more common among non-movement specialty referrals.* Only 3% of myoclonus referrals had a physiologic subtype specified pre-MNS, compared to 89% of myoclonus cases physiologically subtyped by MNS.

The high rate of back-averaging success in our study is likely attributable in part to the extensive EEG and EMG set-up used in our lab, which is enabled by a specialized team with 2 clinical neurophysiology technicians typically working together for approximately 30 minutes setting up electrodes for each case. Ensuring that electrode impedance is <10 kOhm for EMG[17] and EEG leads allows clear visualization of myoclonus discharges and corresponding cortical transients among other muscle and brain activity respectively. EMG coverage of all limbs allows selection among many muscles for the one with the most frequent and well-formed myoclonus discharges for back-averaging. EEG with expanded motor cortex coverage ensures clear capture of cortical transients which may be located slightly off of the typical C3/C4 location. Live supervision and data review by the movement neurophysiology neurologist allows adjustment of the protocol to capture enough myoclonus discharges for back-averaging. The clinical utility of SSEP and LLR were low in this study, as abnormalities were seen only in patients who also had a cortical transient on back-averaging, though SSEP and LLR use is limited in our lab, and corticomuscular coherence has only rarely been utilized.

Even with a myoclonus-optimized set-up, there are some limitations to MNS clinical utility in jerky movements. In the authors' experience, reliable EMG-EEG back-averaging generally requires capturing at least 50 and ideally 100 jerky movements for maximum sensitivity in detecting a cortical transient. Back-averaging may be attempted with fewer jerky movements, but absence of a cortical correlate in such cases may not exclude cortical myoclonus physiology, especially if other cortical myoclonus features are present. Infrequent or intermittent jerky movements may not be adequately captured during the limited time available for laboratory MNS, and ambulatory set-ups are not currently feasible. Additionally, jerky movements that cause large-amplitude head movements may obscure the EEG recording despite optimal electrode placement and fixation, preventing reliable back-averaging.

85% of clinicians specifically discussed the MNS findings in their diagnostic and treatment decision making. While the focus of MNS are on movement classification rather than etiologic diagnosis, a valuable contribution to diagnostic reasoning is indicated by the trend of differential diagnosis narrowing in 60% of cases (Fig 3), and by new diagnoses established or added to the differential in 71 (24%) cases. The majority (52%) of patients also had a change in medication management post-MNS, with the most common medication changes for cortical, subcortical/non-segmental, and segmental myoclonus aligning with published recommendations.[10]

As a real-world retrospective study, there are some clear limitations to our findings. Clinicians did not always comprehensively document patient history, characteristics, medications, and their movement classification and diagnostic differential, especially pre-MNS. Higher rates of pre-MNS neurologic exam

abnormalities besides hyperkinetic movements in post-MNS myoclonus patients compared to non-myoclonus patients (56% vs 4%) may be a helpful clue that myoclonus is less likely when the neurologic exam is largely normal, but this finding could be attributable to clinicians performing and/or documenting a more detailed neurologic exam in some patients, even before myoclonus was identified on MNS. More broadly, MNS referral was not random, but concentrated on patients with complex movement/neurologic phenotypes unable to be fully characterized on clinical exam. The high rate of successful physiologic subtyping in this study left only a small group of myoclonus subtype indeterminate post-MNS, the majority of whom had predominant non-myoclonus movements, so this group could not be utilized as a "control" group for statistical comparison of myoclonus subtyping utility. Many subjects had other tests completed concurrently with MNS including laboratory testing and imaging, and so not all the changes in diagnostic differential and treatment can be attributed solely to MNS findings (clinician documentation of prior test results reviewed and new tests ordered during pre-MNS consultation was inconsistent, and EHR records of test names and timing of ordering and results varied substantially among the different EHR platforms in place over the 14-year time period of our study, preventing detailed investigation). However, the high rates of MNS clarifying movement classification and clinician documentation of MNS utility support its clinical impact being substantial and distinct from other test results. Prospective studies with standardized capture of movement classification certainty, diagnostic differential, concurrent testing, and clinical decision-making may provide higher quality evidence to investigate MNS utility. This study also focused on myoclonus: MNS techniques have also been established for tremor characterization,[18] but other abnormal movement classifications require more qualitative interpretation of MNS data.[9]

In conclusion, this study provides extensive real-world evidence that MNS can effectively clarify movement classification and physiologic subtype in cases of possible myoclonus, and MNS findings are associated with clinically useful and impactful changes in diagnostic reasoning and patient treatment. Greater adoption and clinical use of these studies in movement specialty centers may be clinically beneficial for patient care: interested clinicians are referred to Supplement 1, recent practical reviews of myoclonus movement studies,[11,19] the new freely accessible Handbook of Clinical Neurophysiology: Movement Disorders series,[1,20] and the Movement Disorder Society (MDS) Clinical Neurophysiology Study Group (https://www.movementdisorders.org/MDS/About/Committees--Other-Groups/Study-Groups/Clinical-Neurophysiology.htm). Moreover, referral of cases of myoclonus and possible myoclonus to centers that perform MNS should be encouraged.

Acknowledgements

Kate Rogers, Lynn Sigston, Chris Harris, and multiple other clinical neurophysiology technicians have been essential collaborators in performing MNS over the years. Apurva Khanna assisted with the MNS billing database search. Sam D. Peterson assisted with the EHR search. Ryan Callister assisted with data analysis techniques. No funding was received for this research study.

Author Contributions

Marcus N. Callister M.D.: conception and design of the study, acquisition and analysis of data, drafting a significant portion of the manuscript and figures
Molly C. Klanderman Ph.D., M.S.: conception and design of the study, acquisition and analysis of data
Alyssa Stockard: conception and design of the study, acquisition and analysis of data, drafting a significant portion of the manuscript

Charles Van Der Walt: conception and design of the study, acquisition and analysis of data, drafting a significant portion of the manuscript and figures
Ashley B. Pena M.D.: conception and design of the study
John N. Caviness M.D.: conception and design of the study, acquisition and analysis of data

Potential Conflicts of Interest

Marcus N. Callister M.D.: nothing to report
Molly C. Klanderman Ph.D., M.S.: nothing to report
Alyssa Stockard: nothing to report
Charles Van Der Walt: nothing to report
Ashley B. Pena M.D.: nothing to report
John N. Caviness M.D.: nothing to report

Data Availability

REDCap data collection instrument design and format are included in supplement 2.1, 2.2, and 2.3. The data that support the findings of this study are available on request from the corresponding author, pending institutional approval. The data are not publicly available due to privacy and ethical restrictions on individual patient clinical health data.

Figures

Figure 1: Inclusion/Exclusion Flow Chart

Figure 1 Legend: Flow chart illustrating cohort selection.

Figure 2: Abnormal Movement Classification Shift from pre-MNS to post-MNS, by Clinician type

Figure 2 Legend: Alluvial plot illustrating shift in movement classification (certainty/uncertainty regarding presence of myoclonus, see Methods section for details) from before MNS to after MNS, among MNS referrals from movement specialty neurologists (upper panel) and non-movement specialty neurologists (lower panel).

Figure 3: Diagnostic Differential Shift from pre-MNS to post-MNS, by Clinician Type

Figure 3 Legend: Alluvial plot illustrating shift in diagnostic differential (single diagnosis, narrow: ≤3 possible diagnoses, broad: >3 possible diagnoses, or unknown/unspecified/highly uncertain) from before MNS to after MNS, among MNS referrals from movement specialty neurologists (left panel) and non-movement specialty neurologists (right panel). The predominant shift is from broad/unknown to single/narrow. Dx: diagnosis, ddx: diagnostic differential, MNS: movement neurophysiology study.

Tables

Table 1: Myoclonus physiologic subtypes

Electrophysiologic Subtype	MNS Features	Examples
Cortical	- EMG burst duration brief, especially <50 msec - Agonist-antagonist co-contraction - Multifocal or focal distribution - Focal EEG transient preceding myoclonus - Enlarged cortical SSEP - Enhanced LLR - Exaggerated cortico-muscular coherence	Toxic-metabolic Neurodegenerative Post-hypoxic Progressive myoclonic epilepsy
Cortical-subcortical	- EMG burst duration <100 msec - Bilateral or generalized distribution - Generalized spike and wave EEG discharge preceding myoclonus	Myoclonic seizures

Subcortical/non-segmental	1) Rostral-caudal spreading pattern
	2) Multifocal pattern
	  - EMG burst duration often >100 msec, but variable
	  - Variable agonist-antagonist pattern
	  - No focal EEG transient
		Reticular reflex myoclonus
		Myoclonus-dystonia

Segmental	- EMG burst duration often >100 msec - Rhythmic or semi-rhythmic - Contiguous segments of brainstem and/or spinal cord	Palatal myoclonus Spinal myoclonus
Peripheral	- Myoclonus in a single nerve distribution	Hemifacial spasm

Table 2: Subjects Description

	All subjects (n=291)	Myoclonus post-MNS (n=135*)	Referred for ? myoclonus, none post-MNS (n=156)
Age	55 (20)	58 (20)	53 (19)
Sex: female	153 (52%)	71 (53%)	81 (52%)
Race			
American Indian	2 (1%)	1 (1%)	1 (1%)
Asian	4 (1%)	2 (1%)	2 (1%)
Black	3 (1%)	1 (1%)	2 (1%)
White	275 (94%)	128 (95%)	146 (94%)
Other/Unknown	8 (3%)	3 (2%)	5 (3%)
Ethnicity: Hispanic	17 (6%)	7 (5%)	10 (6%)
Pre-MNS clinician: Movement neurology	227 (78%)	101 (75%)	125 (81%)
Duration of abnormal movements (months)	12 (5-42)	12 (5-41)	7 (5-65)
Time from consult to MNS (days)	8 (1-29)	9 (1-35)	6 (1-23)
Time from MNS to follow-up (days)	5 (1-20)	5 (1-21)	6 (1-20)

Table 2 Legend: categorical variables are given as count (percentage). Continuous variables are given as mean (standard deviation) for normally distributed data (age), or median (quartile 1 to quartile 3) for non-normally distributed data (duration of abnormal movements, time from consult to MNS, and time from MNS to follow-up)

*This includes the 1 patient with final post-MNS classification of uncertain myoclonus.

Table 3: MNS Neurophysiologic Data by Myoclonus Subtype

	Cortical	Subcortical-Nonsegmental	Segmental		Fragmentary		Subtype Indeterminate
n	64	22	15		17		15
Duration							
- <50	38, 59%	3, 14%	0		1, 6%		5, 33%
- 50-100	24, 35%	11, 50%	3, 20%		12, 71%		7, 47%
- 100-200	4, 6%	13, 59%	10, 67%		8, 47%		3, 20%
- >200	2, 3%	6, 27%	3, 20%		1, 6%		0
Overlap*	8, 13%	11, 50%	3, 20%		7, 41%		3, 20%
Agonist-antagonist							
- Co-contracting	36, 56%	8, 36%	4, 27%		11, 65%		5, 33%
- Reciprocal	0	1, 5%	1, 7%		0		1, 7%
- Agonist only	3, 5%	1, 5%	0		3, 18%		0
Location							
- Single limb	6, 9%	0	1, 1%		2, 12%		2, 13%
- Multiple limbs	54, 84%	16, 72%	1, 1%		10, 59%		11, 73%
- Trunk/neck	6, 9%	9, 41%	9, 60%		2, 12%		2, 13%
- Face/pharynx	4, 6%	2, 9%	4, 27%		0		1, 6%
EEG correlate							
- Present raw EEG	1, 2%	0	0		0		0
- Present back-avg	62, 97%	0	0		0		0
- Absent back-avg	1, 2%	14, 63%	4, 27%		2, 12%		9, 60%
- Too few/unable	0	1, 5%	1, 7%		4, 24%		6, 40%
- Not assessed	0	7, 32%**	10, 67%		11, 65%		0
Giant SEP							
- Present	6, 9%	0	0		0		0
- Absent	14, 22%	2, 9%	0		0		1, 7%
- Not assessed	44, 69%	20, 91%	15, 100%		17, 100%		14, 93%
Enhanced LLR							
- Present	8, 13%	0	0		0		0
- Absent	12, 19%	2, 9%	0		0		1, 7%
- Not assessed	44, 69%	20, 91%	15, 100%		17, 100%		14, 93%
Coexisting: any	25, 39%	9, 41%	2, 13%		9, 53%		10, 67%
- Tremor activation-	15, 23%	5, 23%	0		4, 24%		8, 53%
Tremor rest	1, 2%	1, 5%	0		0		1, 7%
- Tremor physiologic	0	0	1, 7%		2, 12%		0
- Dystonia	1, 2%	3, 14%	0		0		2, 13%
- Bradykinesia	1, 2%	0	0		0		3, 20%
- RLS	0,	1, 5%	0		3, 18%		0
- FMD	2, 3%	0	1, 7%		2, 12%		0

*Burst durations overlapping multiple categories, e.g. 50-150 and 100-300 (patients therefore included in multiple duration categories above). **All of these cases had burst duration >100 msec. Data missing/unable to determine: duration n=6, pattern n=13, no missing data for other variables.

Table 4: Movement classifications among 156 patients referred for myoclonus and found to have no myoclonus on MNS

Movement type	n, %
FND	54, 35%
Tremor in activation	45, 29%
Tremor in rest	20, 13%
Spasms nonspecific	14, 9%
RLS	13, 8%
Tremor physiologic	10, 6%
Tics	9, 6%
Dystonia	9, 6%
Chorea	7, 4%
Ataxia	4, 3%
Tremor orthostatic	4, 3%
Tardive dyskinesia	2, 1%
Other	12, 8%

Some patients had more than one non-myoclonus movement classification present (e.g. tremor in activation and tremor in rest). FND: functional neurological disorder, RLS: restless legs sydnrome

Table 5: Post-MNS Diagnosis, Management of by Myoclonus Subtype

	Cortical	Subcortical-Nonsegmental	Segmental		Fragmentary		Subtype Indeterminate
n	64	22	15		17		15
Post-MNS Ddx							
- Single dx	21, 33%	12, 55%	12, 80%		15, 88%		5, 33%
- Narrow ddx	21, 33%	5, 23%	0		1, 6%		4, 27%
- Broad ddx	11, 17%	3, 14%	3, 20%		1, 6%		1, 7%
- Unknown	11, 17%	2, 9%	0		0		5, 33%
Any med change?	47, 73%	14, 63%	11, 73%		6, 35%		8, 53%
Top 3 Rx / ↑							
- Levetiracetam	18, 28%	3, 14%	2, 13%		0		3, 20%
- Benzodiazepine	5, 8%	4, 18%	6, 40%		4, 24%		1, 6%
- Valproate	2, 3%	0	0		0		1, 6%
Top 3 Stop / ↓							
- Gabapentinoids	4, 6%	1, 5%	0		1, 6%		1, 6%
- Bupropion	3, 5%	0	0		0		0
- TCAs	2, 3%	0	0		0		0
Med change f/u?	22, 47%	6, 43%	3, 20%		1, 6%		4, 27%
Myoclonus							
- Very improved	8, 36%	2, 33%	2, 67%		0		4, 100%
- Slight improved	6, 27%	1, 17%	1, 33%		1, 100%		0
- No change	8, 36%	3, 50%	0		0		0
- Worse	0	0	0		0		0
Adverse Effects							
- None	7, 32%	2, 33%	2, 67%		1, 100%		3, 75%
- Mild	4, 18%	0	1, 33%		0		1, 25%
- Moderate	7, 32%	2, 33%	0		0		0
- Severe	0	0	0		0		0

References

1. Veen S van der, Caviness JN, Dreissen YEM, et al. Myoclonus and other jerky movement disorders. Clin. Neurophysiol. Pr. 2022;7:285–316.

2. Caviness JN. Myoclonus. Continuum Lifelong Learn Neurology 2019;25(4):1055–1080.

3. Zutt R, Elting JW, Hoeven JH van der, et al. Myoclonus subtypes in tertiary referral center. Cortical myoclonus and functional jerks are common. Clin Neurophysiol 2017;128(1):253–259.

4. Halliday A. The Electrophysiological Study of Myoclonus in Man. Brain 1967;90(2):241–284.

5. Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, editors. Movement Disorders. Butterworth-Heinemann; 1981 p. 196–248.

6. Shibasaki H. AAEE minimonograph #30: Electrophysiologic studies of myoclonus. Muscle Nerve 1988;11(9):899–907.

7. Hallett M, DelRosso LM, Elble R, et al. Evaluation of movement and brain activity. Clin Neurophysiol 2021;132(10):2608–2638.

8. Zutt R, Elting JW, Zijl JC van, et al. Electrophysiologic testing aids diagnosis and subtyping of myoclonus. Neurology 2018;90(8):10.1212/WNL.0000000000004996.

9. Veen S van der, Klamer MR, Elting JWJ, et al. The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: a systematic review. Parkinsonism Relat D 2021;89:176–185.

10. Pena AB, Caviness JN. Physiology-Based Treatment of Myoclonus. Neurotherapeutics 2020;17(4):1665–1680.

11. Vial F, Merchant SHI, McGurrin P, Hallett M. How to Do an Electrophysiological Study of Myoclonus. J. Clin. Neurophysiol. 2023;40(2):93–99.

12. Kassavetis P, Chen R, Ganos C, et al. Global Perceptions and Utilization of Clinical Neurophysiology in Movement Disorders. Mov. Disord. Clin. Pr. 2024;

13. Gandhi SE, Silverdale MA, Mercer D, et al. Real world use of a neurophysiology service for the differential diagnosis of hyperkinetic movement disorders. Park. Relat. Disord. 2020;71:11–14.

14. Everlo CSJ, Elting JWJ, Tijssen MAJ, Stouwe AMM van der. Electrophysiological testing aids the diagnosis of tremor and myoclonus in clinically challenging patients. Clin Neurophysiology Pract 2022;7:51–58.

15. Grippe T, Chen R. Utility of Neurophysiological Evaluation in Movement Disorders Clinical Practice. Mov. Disord. Clin. Pr. 2023;10(11):1599–1610.

16. Elm E von, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335(7624):806.

17. Hermens HJ, Freriks B, Disselhorst-Klug C, Rau G. Development of recommendations for SEMG sensors and sensor placement procedures. J. Electromyogr. Kinesiol. 2000;10(5):361–374.

18. Deuschl G, Becktepe JS, Dirkx M, et al. The clinical and electrophysiological investigation of tremor. Clin Neurophysiol 2022;136:93–129.

19. Vial F, Attaripour S, McGurrin P, Hallett M. BacAv, a new free online platform for clinical back-averaging. Clin Neurophysiology Pract 2020;5:38–42.

20. Ziemann U, Seeck M. The new Handbook Series of Clinical Neurophysiology. Clin Neurophysiology Pract 2021;6:244–244.